GAMMA Investing LLC Has $11.23 Million Position in Haemonetics Co. (NYSE:HAE)

GAMMA Investing LLC increased its position in Haemonetics Co. (NYSE:HAE - Free Report) by 11,225.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,667 shares of the medical instruments supplier's stock after purchasing an additional 17,511 shares during the quarter. GAMMA Investing LLC's holdings in Haemonetics were worth $11,230,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in Haemonetics during the 4th quarter valued at $402,000. Empowered Funds LLC bought a new position in shares of Haemonetics in the 4th quarter worth about $319,000. Allspring Global Investments Holdings LLC lifted its position in shares of Haemonetics by 0.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock worth $62,802,000 after buying an additional 5,668 shares during the last quarter. Van ECK Associates Corp bought a new position in shares of Haemonetics in the 4th quarter worth about $3,094,000. Finally, Vontobel Holding Ltd. lifted its position in shares of Haemonetics by 166.7% in the 4th quarter. Vontobel Holding Ltd. now owns 13,011 shares of the medical instruments supplier's stock worth $1,016,000 after buying an additional 8,133 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Down 0.8%

Shares of Haemonetics stock traded down $0.61 during trading on Wednesday, hitting $71.53. The stock had a trading volume of 549,676 shares, compared to its average volume of 681,154. The stock has a 50 day simple moving average of $64.63 and a 200 day simple moving average of $69.42. The company has a market capitalization of $3.44 billion, a PE ratio of 28.16, a P/E/G ratio of 1.11 and a beta of 0.36. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.90 earnings per share. On average, research analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HAE. JMP Securities restated a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a research report on Tuesday, May 20th. Raymond James restated a "strong-buy" rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Needham & Company LLC reduced their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $97.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.